How the Treatment of Lung Cancer Has Been Transformed in the Era of Molecular Biomarker Testing

Video Library —July 18, 2018
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine
Chief of Medical Oncology
Director, Thoracic Oncology Research Program Associate Director for Translational
Research Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, CT
David L Rimm, MD, PhD
Drs Roy Herbst and David Rimm review how biomarker testing has transformed the way patients with lung cancer are treated, and how both medical oncologists and pathologists contribute to these changes.
Related Articles
Navigating Lung Cancer Patients at Fox Chase Cancer Center
August 2018 Vol 9, No 8
An Interview with Maria Kadlec, BSN, RN; Caryn M. Vadseth, BSN, RN, OCN; and Mary Pat Winterhalter, MS, BSN, RN, NE-BC
How Molecular Biomarkers Have Impacted Cancer Treatment
Geoff Oxnard, MD, Lauren Ritterhouse, MD, PhD
|
Video Library
Drs Geoffrey Oxnard and Lauren Ritterhouse discuss the challenges and opportunities of precision medicine and molecular biomarkers in their clinical practice from an oncologist’s and a pathologist’s perspective.
Optimizing Communication Between Oncologists and Pathologists on Cancer Biomarker Testing
Geoff Oxnard, MD, Lauren Ritterhouse, MD, PhD
|
Video Library
Drs Geoffrey Oxnard and Lauren Ritterhouse discuss the best ways oncologists and pathologists can communicate about molecular biomarker testing for individual patients as well as on strategies for incorporating new biomarkers into testing panels.
Last modified: July 30, 2018

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code